Abstract
Development of vitiligo-like hypopigmentary lesions associated with topical imiquimod has been reported. We hypothesized that mode of action of imiquimod in melanocytes may include triggering of apoptosis resulted in loss of cells, which may be a possible mechanism of imiquimod-induced hypopigmentary lesions. Therefore, we investigated whether imiquimod induces apoptosis of human melanocytes and also whether it modulates expression of apoptosis-related molecules in human melanocytes. Imiquimod treatment induced apoptosis of melanocytes, which was observed by TUNEL assay and Hoechst 33258 staining. Imiquimod-induced apoptosis was further shown by measuring mitochondrial membrane potential in melanocytes. The apoptotic activity of imiquimod was associated with caspase-3, Bcl-2 and mitogen-activated protein kinase expression in melanocytes. These results indicated that imiquimod induces apoptosis of melanocytes. These findings may provide a clue to understand pathogenesis of imiquimod-induced vitiligo-like hypopigmentary lesions.
This is a preview of subscription content, log in via an institution to check access.
References
Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML (1999) Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 41:1002–1007
Brown T, Zirvi M, Cotsarelis G, Gelfand JM (2005) Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. J Am Acad Dermatol 52:715–716
Choi TY, Kim JH, Ko DH et al (2007) Zebrafish as a new model for phenotype-based screening of melanogenic regulatory compounds. Pigment Cell Res 20:120–127
Dahl MV (2002) Imiquimod: a cytokine inducer. J Am Acad Dermatol 47:S205–S208
Du J, Miller AJ, Widlund HR, Horstmann MA, Ramaswamy S, Fisher DE (2003) MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol 163:333–343
Goding CR (2000) Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev 14:1712–1728
Gowda S, Tillman DK, Fitzpatrick JE, Gaspari AA, Goldenberg G (2009) Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma. Cutan Pathol 36:878–881
Inglefield JR, Larson CJ, Gibson SJ, Lebrec H, Miller RL (2006) Apoptotic responses in squamous carcinoma and epithelial cells to small-molecule toll-like receptor agonists evaluated with automated cytometry. J Biomol Screen 11:575–585
Jacob SE, Berman B, Nassiri M, Vincek V (2003) Topical application of imiquimod 5% cream to keloids alters expression genes associated with apoptosis. Br J Dermatol 149:62–65
Kang HY, Lee JY, Lee JS, Choi YM (2007) Peroxisome proliferator-activated receptors-γ activator, ciglitazone, inhibits human melanocyte. Exp Dermatol 16:118–123
Kang HY, Park TJ, Jin SH (2009) Imiquimod, a Toll-like receptor 7 agonist, inhibits melanogenesis and proliferation of human melanocytes. J Invest Dermatol 129:243–246
Kimura S, Kawakami T, Kawa Y et al (2005) Bcl-2 reduced and fas activated by the inhibition of stem cell factor/KIT signaling in murine melanocyte precursors. J Invest Dermatol 124:229–234
Kitamura R, Tsukamoto K, Harada K et al (2004) Mechanisms underlying the dysfunction of melanocytes in vitiligo epidermis: role of SCF/KIT protein interactions and the downstream effector, MITF-M. J Pathol 202:463–475
McGill GG, Horstmann M, Widlund HR et al (2002) Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 14:707–718
Meyer T, Nindl I, Schmook T, Ulrich C, Sterry W, Stockfleth E (2003) Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. Br J Dermatol 149:9–14
Ongenae K, Van Geel N, Naeyaert JM (2003) Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 16:90–100
Park HY, Wu C, Yonemoto L et al (2006) MITF mediates cAMP-induced protein kinase C-beta expression in human melanocytes. Biochem J 395:571–578
Passeron T, Ortonne JP (2005) Physiopathology and genetics of vitiligo. J Autoimmun 25(Suppl):63–68
Peus D, Vasa RA, Beyerle A et al (1999) UVB activates ERK1/2 and p38 signaling pathways via reactive oxygen species in cultured keratinocytes. J Invest Dermatol 112:751–756
Sauder DN (2000) Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 43:S6–S11
Schön MP, Wienrich BG, Drewniok C et al (2004) Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol 122:1266–1276
Stefanaki C, Nicolaidou E, Hadjivassiliou M, Antoniou C, Katsambas A (2006) Imiquimod-induced vitiligo in a patient with genital warts. J Eur Acad Dermatol Venereol 20:755–756
Vidal D, Matías-Guiu X, Alomar A (2004) Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. Br J Dermatol 15:656–662
Ulrich C, Busch JO, Meyer T et al (2006) Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol 155:451–454
Acknowledgments
This work was supported by 2005 grant from Department of Medical Sciences, The Graduate School, Ajou University and “GRRC” Project of Gyeonggi Provincial Government, Republic of Korea.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, CH., Ahn, J.H., Kang, S.U. et al. Imiquimod induces apoptosis of human melanocytes. Arch Dermatol Res 302, 301–306 (2010). https://doi.org/10.1007/s00403-009-1012-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-009-1012-0